Biofortis Research, Addison, IL, USA.
Yakult Honsha Co., Ltd, Tokyo, Japan.
Int J Food Sci Nutr. 2023 Sep;74(5):645-653. doi: 10.1080/09637486.2023.2246693. Epub 2023 Aug 16.
The probiotic strain (previously ) strain Shirota (LcS) has demonstrated its survivability in the gastrointestinal tract across populations in different countries. The objective of this study was to validate this survivability in the United States, where evidence is lacking. Faecal samples were collected from 26 healthy individuals (age: 32.0 ± 5.9 years) at baseline, after 7 and 14 days of daily consumption of 80 mL fermented milk containing 10 colony forming units (CFU) LcS/mL, and after a subsequent 14-days of no product consumption. Live LcS counts significantly ( < 0.001) increased after 7 and 14 days of product consumption (6.37 ± 1.18 and 5.24 ± 1.81 log CFU/g faeces, respectively) and returned to baseline in 87% of participants. These results indicate LcS survives passage through the gastrointestinal tract of generally healthy U.S. adults, providing support for its uniquely accumulated evidence of universal survival capacity in the gastrointestinal tract.
该益生菌菌株（以前称为）Shirota（LcS）已证明其在不同国家的人群中的胃肠道中的生存能力。本研究的目的是在美国验证这种生存能力，因为目前缺乏相关证据。在基线时、连续 7 天和 14 天每天摄入 80 毫升含有 10 个菌落形成单位（CFU）/毫升 LcS 的发酵乳以及随后的 14 天不摄入产品后，从 26 名健康个体（年龄：32.0±5.9 岁）中收集粪便样本。在产品摄入 7 天和 14 天后，LcS 的活菌数明显（<0.001）增加（粪便中分别为 6.37±1.18 和 5.24±1.81 log CFU/g），并在 87%的参与者中恢复到基线水平。这些结果表明 LcS 能够在一般健康的美国成年人的胃肠道中通过，为其在胃肠道中具有普遍生存能力的独特累积证据提供了支持。
